Global Vaccine Adjuvants Market:
Vaccine adjuvants are the substances added to the vaccines for enhancing the vaccine ability to protect against the infection. Vaccine adjuvants improve the immunogenicity of purified antigens, which has immunostimulatory capabilities and has been used in the vaccines for more than 90 years. Nowadays, a very less number of vaccine adjuvants are available such as MF 59 and aluminium salts. Vaccines are combined with the adjuvants to ensure body produces an efficient immune response to protect the person against the infection.
Increase in the prevalence of various zoonotic and other infectious diseases, increase in the demand for improved vaccination against various diseases, government focus on organizing the immunization programs, an increase in the use of synthetic and recombinant vaccines anticipated to propel the vaccine adjuvants market over the forecast period. Furthermore, increase in the prevalence of livestock & companion animal diseases, technological advancements in the aluminum hydroxide adjuvants, and government support for R&D activities are anticipated to fuel the vaccine adjuvants market over the forecast period. However, stringent regulatory policies, side effects associated with the adjuvants usage, and high cost for the R&D activities might impede the growth of vaccine adjuvants market over the forecast period.
Vaccine adjuvants market is segmented on the basis of product type, vaccine type, route of administration, application, and end user
Based on the product type, vaccine adjuvants market is segmented into the following:
- Pathogen components
- Combination adjuvants
- Particulate adjuvants
- Adjuvant emulsions
Based on the vaccine type, vaccine adjuvants market is segmented into the following:
- Human vaccines
- Veterinary vaccines
Based on the route of administration, vaccine adjuvants market is segmented into the following:
Based on application, vaccine adjuvants market is segmented into the following:
- Infectious diseases
Based on the end user, vaccine adjuvants market is segmented into the following:
- Pharmaceutical industries
- Biotechnology industries
- Veterinary vaccine manufacturing industries
Vaccine adjuvants market is growing at a significant CAGR owing to increase in the prevalence of infectious diseases in humans, livestock & companion animals around the globe. Growing need for enhancing immune response and limited immunogenicity of novel vaccines expected to fuel the vaccine adjuvants market. Acquisitions and mergers, collaborations, and novel adjuvant introductions are the strategies applied by the market players to dominate the vaccine adjuvants market. For instance, in August 2013, FDA approved the Sequirus’s Afluria quadrivalent vaccine for people with 18 years or older. Similarly, funding by the government organizations to augment adjuvants research is anticipated to boost the vaccine adjuvants market. For instance, in April 2016, National Institute of Allergy and Infectious Diseases awarded 6 grants to various organizations including universities such as University of Wisconsin about US$ 3.1 Mn grants for vaccine adjuvants research.
Geographically, vaccine adjuvants market is segmented into North America, Latin America, Asia Pacific, Europe, and Middle East & Africa. North America is expected to hold a major share in vaccine adjuvants market owing to rise in the incidence of infectious diseases, government initiatives for organizing immunization programs, an increase in the collaborations for R&D activities on vaccine adjuvants are fuelling the market. For instance, in July 2016, U.S. Army Medical Research Institute of Infectious Diseases has collaborated with China’s Jilin Jian Yisheng Biopharma for the development of Ebola PIKA adjuvant vaccine. Europe holds a significant share in vaccine adjuvants market owing to rising in the prevalence of cancer, influenza, and other infectious diseases, increase the awareness about the vaccine adjuvant applications in the manufacturing of vaccines, and rise in the R&D activities are expected to propel the market growth. Asia Pacific vaccine adjuvants market is growing significantly due to rise in birth rate, increase in the prevalence of various infectious diseases, and development of newer adjuvants for improving the vaccine immunization.
Some of the players in vaccine adjuvants market are Invivogen (U.S.), MVP Laboratories, Inc. (U.S.), CSL Limited (Australia), SEPPIC (France), Brenntag Biosector (Denmark), Novavax, Inc. (U.S.), Agenus, Inc. (U.S.), OZ Biosciences (France), and Jilin Jian Yisheng Biopharma Co. Ltd. (China) to name a few.
- In November 2016, The Scripps Research Institute has collaborated with Yisheng Biopharma for testing the Yisheng’s PIKA vaccine adjuvants against HIV infection
- The report provides granular level information about the market size, regional market share, and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments, and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework, and reimbursement scenario